Emergent BioSolutions (EBS) announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent’s strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical and biostatistics, and patient safety. Lowry most recently served as chief executive officer for Mysthera Therapeutics
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- EBS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Emergent BioSolutions Grants CFO Stock for Contributions
- Emergent Biosolutions Secures Loan, Bolsters Growth Strategy
- Emergent BioSolutions closes $100M asset-backed loan facility
- Newsom signs bill pushing for Narcan in workplace first aid kits, LA Times says